Fed or fasted state for oral therapies in breast cancer treatment? A comprehensive review of clinical practice recommendations - ScienceDirect
PARP Inhibitor Improves Odds for Women With Ovarian Cancer and More Cancer News From ASCO's Virtual Annual Meeting | Everyday Health
Improved pharmacodynamic (PD) assessment of low dose PARP inhibitor PD activity for radiotherapy and chemotherapy combination trials - ScienceDirect
Role of PARP Inhibitors in BRCA-Related Malignancies
206162Orig1s000
206162Orig1s000
Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors | SpringerLink
Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies - Clinical Therapeutics
Practical and Scalable Manufacturing Process for the Key Intermediate of Poly(ADP-Ribose) Polymerase Inhibitor Olaparib | ACS Omega
MrMed Blogs: Get useful & latest information about Super Specialty Medicines